Literature DB >> 7673033

Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis.

D Oetzel1, P Schraube, F Hensley, G Sroka-Pérez, M Menke, M Flentje.   

Abstract

PURPOSE: Investigations to study correlations between the estimations of biophysical models in three dimensional (3D) treatment planning and clinical observations are scarce. The development of clinically symptomatic pneumonitis in the radiotherapy of thoracic malignomas was chosen to test the predictive power of Lyman's normal tissue complication probability (NTCP) model for the assessment of side effects for nonuniform irradiation. METHODS AND MATERIALS: In a retrospective analysis individual computed-tomography-based 3D dose distributions of a random sample of 46/20 patients with lung/esophageal cancer were reconstructed. All patients received tumor doses between 50 and 60 Gy in a conventional treatment schedule. Biological isoeffective dose-volume histograms (DVHs) were used for the calculation of complication probabilities after applying Lyman's and Kutcher's DVH-reduction algorithm. Lung dose statistics were performed for single lung (involved ipsilateral and contralateral) and for the lung as a paired organ.
RESULTS: In the lung cancer group, about 20% of the patients (9 out of 46) developed pneumonitis 3-12 (median 7.5) weeks after completion of radiotherapy. For the majority of these lung cancer patients, the involved ipsilateral lung received a much higher dose than the contralateral lung, and the pneumonitis patients had on average a higher lung exposure with a doubling of the predicted complication risk (38% vs. 20%). The lower lung exposure for the esophagus patients resulted in a mean lung dose of 13.2 Gy (lung cancer: 20.5 Gy) averaged over all patients in correlation with an almost zero complication risk and only one observed case of pneumonitis (1 out of 20). To compare the pneumonitis risk estimations with observed complication rates, the patients were ranked into bins of mean ipsilateral lung dose. Particularly, in the bins with the highest patient numbers, a good correlation was achieved. Agreement was not reached for the lung functioning as a paired organ.
CONCLUSIONS: Realistic assessments for the prediction of radiation-induced pneumonitis seem to be possible. In this respect, the implementation of DVH-analysis in 3D planning could be a helpful tool for the evaluation of treatment plans.

Entities:  

Mesh:

Year:  1995        PMID: 7673033     DOI: 10.1016/0360-3016(95)00009-N

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT.

Authors:  Gaurav Kumar; Sheh Rawat; Abhishek Puri; Manoj Kumar Sharma; Pranav Chadha; Anand Giri Babu; Girigesh Yadav
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

2.  Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy.

Authors:  G Alço; S I Iğdem; T Ercan; M Dinçer; R Sentürk; S Atilla; F Oral Zengin; S Okkan
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

Review 3.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

Authors:  Ahmad A Tarhini; Chandra P Belani; James D Luketich; Athanassios Argiris; Suresh S Ramalingam; William Gooding; Arjun Pennathur; Daniel Petro; Kevin Kane; Denny Liggitt; Tony Championsmith; Xichen Zhang; Michael W Epperly; Joel S Greenberger
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

5.  Dosimetric comparison of free-breathing and deep inspiration breath-hold radiotherapy for lung cancer.

Authors:  V Marchand; S Zefkili; J Desrousseaux; L Simon; C Dauphinot; P Giraud
Journal:  Strahlenther Onkol       Date:  2012-05-17       Impact factor: 3.621

6.  Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study.

Authors:  Tseng Tien Huang; Yan Chen; Andrew C Dietz; Yutaka Yasui; Sarah S Donaldson; Dennis C Stokes; Marilyn Stovall; Wendy M Leisenring; Charles A Sklar; Lisa R Diller; Ann C Mertens; Gregory T Armstrong; Daniel M Green; Leslie L Robison; Kirsten K Ness
Journal:  Pediatr Blood Cancer       Date:  2013-10-11       Impact factor: 3.167

7.  Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity.

Authors:  C Nieder
Journal:  Strahlenther Onkol       Date:  2012-08-23       Impact factor: 3.621

8.  Incidence and correlates of radiation pneumonitis in pediatric patients with partial lung irradiation.

Authors:  Chiaho Hua; Kelly A Hoth; Shengjie Wu; Larry E Kun; Monika L Metzger; Sheri L Spunt; Xiaoping Xiong; Mathew J Krasin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

9.  Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.

Authors:  M Moreno; J Aristu; L I Ramos; L Arbea; J M López-Picazo; M Cambeiro; R Martínez-Monge
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

10.  Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy.

Authors:  Giorgia Nicolini; Alessandro Clivio; Antonella Fogliata; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2009-07-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.